CandlesenseCandlesense
News/Companies/SNSE

SNSE News

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

SNSE

(NASDAQ:SNSE) BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025.

September 3, 2025Conference
Read more →

HC Wainwright & Co. Assumes Sensei Biotherapeutics at Buy, Announces Price Target of $5

SNSE

June 2, 2025
Read more →

Sensei Biotherapeutics Q1 EPS $(0.27) Misses $(0.22) Estimate

SNSE

May 6, 2025
Read more →

Oppenheimer Maintains Outperform on Sensei Biotherapeutics, Raises Price Target to $4

SNSE

March 28, 2025
Read more →

Sensei Biotherapeutics Reports FY24 Net Loss Per Share Of $(1.20) Compared With $(1.22) YoY; Says Company Has Cash Runway Into Q2 Of 2026

SNSE

March 28, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Sensei Biotherapeutics, Maintains $4 Price Target

SNSE

March 28, 2025
Read more →

Sensei Biotherapeutics Releases Preliminary Dose Expansion Data For Solnerstotug in PD-(L)1 Resistant Tumors

SNSE

March 27, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Sensei Biotherapeutics, Maintains $4 Price Target

SNSE

January 10, 2025
Read more →